1 冉晶晶,张红雁,薛旭东,等.宫颈癌术后容积调强放疗中限定骨盆剂量的临床研究.中华全科医学,2017,15:152-156. 2 唐滟,袁亚维.调强放疗同步化疗治疗宫颈癌血液学毒性相关因素分析.肿瘤防治研究,2016,43:277-281. 3 Chang Y,Yang ZY,Li GL,et al.Correlations between radiation dose in bone marrow and hematological toxicity in patients with cervical cancer:a comparison of 3DCRT,IMRT,andRapidARC.Int J Gynecol Cancer,2016,26:770-776. 4 高丽环,杨士杰,刘孟奇,等.骨髓保护调强放疗与宫颈癌患者血液学不良反应的相关性.癌症进展,2017,11:1042-1044. 5 Rose B,Mitra D,Hong T S,et al.Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.Int J Radit Oncol,2016,96:198-199. 6 杨洪娟,书阿克·努尔江,谢丛华.宫颈癌调强放疗后骨盆衰竭骨折的发生率及影响因素分析.中华放射医学与防护杂志,2017,37:193-198. 7 Franco P,Ragona R,Arcadipane F,et al.Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.Clin Transl Oncol,2016,19:1-9. 8 张道明,国慧,张奇,等.宫颈癌术后放疗行限定骨盆IMRT计划剂量学分析.中华放射肿瘤学杂志,2017,26:1303-1307. 9 Mabuchi S,Isohashi F,Yokoi T,et al.A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes.Gynecol Oncol,2016,141:240-246. 10 秦迎春.同步放化疗后三维适形放疗与调强放疗宫颈癌患者的血液毒性反应比较.山西医药杂志,2016,45:2856-2858. 11 Mazeron R,Dumas I,Escande A,et al.PO-0938:Should we use point A dose for image-guided adaptive brachytherapy reporting in cervix cancer.Adiother Oncol,2017,123:519-523. 12 王霞,袁红琴,李彦华,等.中晚期子宫颈癌调强放疗同步化疗与常规盆腔野放疗同步化疗效果比较.肿瘤研究与临床,2017,29:386-389. 13 Lee A Y,Golden D,Bazan J G,et al.Hematologic Toxicity During Anal Cancer Treatment:The Importance of Pelvic Bone Marrow Volume and Limiting Radiation Dose to a Critical Marrow Volume.Int JRadiat Oncol,2016,96:216-216. 14 乌晓礼,王利华,阿如汗,等.宫颈癌调强放疗中膀胱的充盈状态对靶区位置的影响.内蒙古医科大学学报,2016,38:389-392. 15 李丹明,王黎,孙新臣,等.中晚期宫颈癌适形调强放疗与容积旋转调强技术临床效果比较.中国医学物理学杂志,2016,33:478-480. 16 赵起.宫颈癌盆腔调强放射治疗的计划靶区变化对危险器官受照容积百分比的影响.河北医药,2016,38:1670-1672.
